Douglas A. Schober - Concepedia

Concepedia

Author

Douglas A. Schober

Eli Lilly (United States)ORCID

Also Known As

D A Schober, D. A. Schober, D. Schober, D.A Schober, D.A. Schober, DOUGLAS A. SCHOBER, Douglas A Schober, Douglas A. Schober, Douglas Schober

62

Publications

3.3K

Citations

32

H-Index

66

Concepts

All Affiliations

Eli Lilly (United States)Uppsala University Indiana University – Purdue University Indianapolis

DA

About

Douglas A. Schober is an author at Eli Lilly (United States) specializing in medicine, neuropharmacology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	33	2.2K
2	Social Sciences	10	10	922
3	Natural Sciences	5	5	312
4	Engineering	1	1	317
5	Public Health	1	1	78

Douglas A. Schober

×

53

Publications

3.3K

Citations

32

H-Index

	Year	Citations
Cloning of a Human Receptor of the NPY Receptor Family with High Affinity for Pancreatic Polypeptide and Peptide YY Ingrid Lundell, Anders Blomqvist, Magnus Berglund, Journal of Biological Chemistry EngineeringHuman ReceptorImmunologyGastrointestinal Peptide HormonePeptide Yy	1995	317
Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses Tammy J. Sajdyk, Douglas A. Schober, Donald R. Gehlert, Behavioural Brain Research Neurobiological MechanismStress HormonePsychiatryNeurophysiologyNeurobiological Factor	1999	189
Autoradiographic localization of subtypes of angiotensin II antagonist binding in the rat brain Donald R. Gehlert, Susan L. Gackenheimer, Douglas A. Schober Neuroscience NeurophysiologyNeuroanatomyMedicinePhysiologyNeuropeptide Receptor	1991	172
Identification of a high-affinity binding site involved in the transport of endocannabinoids Steven A. Moore, George G. Nomikos, Amy K. Dickason-Chesterfield, Proceedings of the National Academy of Sciences Chemical BiologyCannabinoid PharmacologySaturable Anandamide TransporterMolecular PharmacologyHigh-affinity Binding Site	2005	162
Synthesis and Evaluation of a Series of Novel 2-[(4-Chlorophenoxy)methyl]- benzimidazoles as Selective Neuropeptide Y Y1 Receptor Antagonists Hamideh Zarrinmayeh, Anne M. Nunes, Paul L. Ornstein, Journal of Medicinal Chemistry	1998	152
Neuropeptide Y receptor subtypes in the basolateral nucleus of the amygdala modulate anxiogenic responses in rats Tammy J. Sajdyk, Douglas A. Schober, Donald R. Gehlert Neuropharmacology PsychiatryBehavioral NeuroscienceNeuroanatomyNeurotransmitterNeuropeptide Receptor	2002	141
Expression cloning of a human brain neuropeptide Y Y2 receptor Donald R. Gehlert, Lisa S. Beavers, David W. Johnson, Regulatory Peptides G Protein-coupled ReceptorNeurotransmitterExpression CloningMolecular BiologyNeuropeptide Receptor	1996	140
Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala Tammy J. Sajdyk, Douglas A. Schober, David L. Smiley, Pharmacology Biochemistry and Behavior Behavioral NeuroscienceNeurotransmitterAffective NeuroscienceNeuropeptide ReceptorY-y2 Receptors	2002	124
The cloned rat pancreatic polypeptide receptor exhibits profound differences to the orthologous receptor. Ingrid Lundell, M.A. Statnick, David W. Johnson, Proceedings of the National Academy of Sciences Rat PpImmunologyGastrointestinal Peptide HormoneMolecular PharmacologyRat Receptor	1996	109
M1 and M2 Muscarinic Receptor Subtypes Regulate Antidepressant-Like Effects of the Rapidly Acting Antidepressant Scopolamine Jeffrey M. Witkin, C. Overshiner, X. Li, Journal of Pharmacology and Experimental Therapeutics	2014	95

Page 1